{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:58:07Z","timestamp":1784728687935,"version":"3.55.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by an overactive immune response, particularly involving excessive production of type I interferons. This overproduction is driven by the phosphorylation of IRF7, a crucial factor in interferon gene activation. Current treatments for SLE are often not very effective and can have serious side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our study introduces clobenpropit, a histamine analogue, as a potential new therapy targeting the CXCR4 receptor to reduce IRF7 phosphorylation and subsequent interferon production. We employed various laboratory techniques to investigate how clobenpropit interacts with CXCR4 and its effects on immune cells from healthy individuals and SLE patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Clobenpropit binds effectively to CXCR4, significantly inhibiting IRF7 phosphorylation and reducing interferon production. Additionally, clobenpropit lowered levels of pro-inflammatory cytokines in a mouse model of lupus, demonstrating efficacy comparable to the standard treatment, prednisolone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results suggest that clobenpropit could be a promising new treatment for SLE, offering a targeted approach with potential advantages over current therapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1490593","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T05:10:10Z","timestamp":1734325810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The histamine analogue clobenpropit modulates IRF7 phosphorylation and interferon production by targeting CXCR4 in systemic lupus erythematosus models"],"prefix":"10.3389","volume":"15","author":[{"given":"Nassima","family":"Bekaddour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika\u00efa","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Caspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Giorgiutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rodeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Leboulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darragh","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Soulas-Sprauel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Gies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Korganow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Nisole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Herbeuval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.autrev.2010.08.014","article-title":"SLE diagnosis and treatment: When early is early","volume":"10","author":"Doria","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: A continuation of a seventy-six-week phase III parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.4465","article-title":"Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation","volume":"174","author":"Curtsinger","year":"2005","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000534","article-title":"New treatments for systemic lupus erythematosus on the horizon: targeting plasmacytoid dendritic cells to inhibit cytokine production","volume":"8","author":"Davison","year":"2017","journal-title":"J Clin Cell Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107173","article-title":"CSL362 potently and specifically depletes pDCs in vitro and ablates SLE-immune complex-induced IFN responses","volume":"26","author":"Monaghan","year":"2023","journal-title":"iScience"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.160","article-title":"Depleting plasmacytoid dendritic cells: a new therapeutic approach in SLE","volume":"10","author":"Onuora","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14253","article-title":"Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement","volume":"8","author":"Smith","year":"2017","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.78","article-title":"Discriminating self from non-self in nucleic acid sensing","volume":"16","author":"Schlee","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042372","article-title":"Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction","volume":"201","author":"Uematsu","year":"2005","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.03.003","article-title":"IRF7, a functional factor associates with systemic lupus erythematosus","volume":"58","author":"Xu","year":"2012","journal-title":"Cytokine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2011.01.006","article-title":"Interferon regulatory factors in human lupus pathogenesis","volume":"157","author":"Salloum","year":"2011","journal-title":"Transl Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni1141","article-title":"Plasmacytoid dendritic cells in immunity","volume":"5","author":"Colonna","year":"2004","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1236923","article-title":"IRF7: role and regulation in immunity and autoimmunity","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.3.1535","article-title":"Regulation of IFN regulatory factor-7 and IFN-\u03b1 Production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells1","volume":"173","author":"Dai","year":"2004","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.27182","article-title":"Genetic variation at the IRF7\/PHRF1 locus is associated with autoantibody profile and serum interferon-\u03b1 activity in lupus patients","volume":"62","author":"Salloum","year":"2010","journal-title":"Arthritis Rheumatism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/382829a0","article-title":"The lymphocyte chemoattractant SDF-1 is a ligand for LESTR\/fusin and blocks HIV-1 entry","volume":"382","author":"Bleul","year":"1996","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.1.111","article-title":"The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood","volume":"185","author":"Aiuti","year":"1997","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1999.9405","article-title":"Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4","volume":"213","author":"McGrath","year":"1999","journal-title":"Dev Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4523","article-title":"The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1","volume":"91","author":"M\u00f6hle","year":"1998","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903196761","article-title":"Targeting the CXCR4\/CXCL12 axis in systemic lupus erythematosus","volume":"13","author":"Chong","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/jm200568c","article-title":"Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4)","volume":"55","author":"Choi","year":"2012","journal-title":"J Med Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/thno.5376","article-title":"Small molecule inhibitors of CXCR4","volume":"3","author":"Debnath","year":"2013","journal-title":"Theranostics"},{"key":"B33","unstructured":"Chemokine Receptor CXCR4 Antagonist - an overview | ScienceDirect Topics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0434-9","article-title":"A randomized, open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC)","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Target Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9524075","article-title":"Role of histamine in modulating the immune response and inflammation","volume":"2018","author":"Branco","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000090280","article-title":"The role of histamine in regulation of immune responses","volume":"91","author":"Jutel","year":"2006","journal-title":"Chem Immunol Allergy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1067\/mai.2003.1585","article-title":"Histamine in the immune regulation of allergic inflammation","volume":"112","author":"Akdis","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9405","DOI":"10.1038\/s41598-021-88829-w","article-title":"Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects","volume":"11","author":"Meghnem","year":"2021","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00120","article-title":"Histamine: a new immunomodulatory player in the neuron-glia crosstalk","volume":"8","author":"Rocha","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/271694","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"Perry","year":"2011","journal-title":"BioMed Res Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178172","article-title":"Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis","volume":"14","author":"Bekaddour","year":"2023","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2472555218797078","article-title":"Identification of primary natural killer cell modulators by chemical library screening with a luciferase-based functional assay","volume":"24","author":"Hayek","year":"2019","journal-title":"SLAS Discovery"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013319117","article-title":"Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists","volume":"117","author":"I\u015fbilir","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/mol.119.118448","article-title":"Kinetic analysis of the early signaling steps of the human chemokine receptor CXCR4","volume":"98","author":"Perpi\u00f1\u00e1-Viciano","year":"2020","journal-title":"Mol Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315627202","article-title":"Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.002","article-title":"Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN","volume":"102","author":"Dieudonn\u00e9","year":"2019","journal-title":"J Autoimmun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310389100","article-title":"IL-17-producing T cells in lupus nephritis","volume":"20","author":"Apostolidis","year":"2011","journal-title":"Lupus"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78085","article-title":"Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity","volume":"125","author":"Burkett","year":"2015","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.01.019","article-title":"Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity","volume":"127","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar4277","article-title":"Clinical associations of serum interleukin-17 in systemic lupus erythematosus","volume":"15","author":"Vincent","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111747","article-title":"Interferon lambda regulates cellular and humoral immunity in pristane-induced lupus","volume":"22","author":"Aschman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 Receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Design Dev Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1916897117","article-title":"Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus","volume":"117","author":"Goel","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310394897","article-title":"Hematopoietic stem cell transplant for systemic lupus erythematosus: Interferon regulatory factor 7 activation correlates with the IFN signature and recurrent disease","volume":"20","author":"Sweeney","year":"2011","journal-title":"Lupus"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B66","article-title":"Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus","volume":"33","author":"Hanaoka","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.47","article-title":"Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus","volume":"14","author":"Zhao","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801920","article-title":"CXCR4\/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus","volume":"182","author":"Wang","year":"2009","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1714765115","article-title":"Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges","volume":"115","author":"Piasecka","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041385","article-title":"Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist","volume":"201","author":"Broxmeyer","year":"2005","journal-title":"J Exp Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00429","article-title":"Diversity and inter-connections in the CXCR4 chemokine receptor\/ligand family: molecular perspectives","volume":"6","author":"Pawig","year":"2015","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1039\/c6ob01484d","article-title":"Design, synthesis, and biological evaluation of CXCR4 ligands","volume":"14","author":"Mona","year":"2016","journal-title":"Org Biomol Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155533","article-title":"Differential levels of IFN\u03b1 subtypes in autoimmunity and viral infection","volume":"144","author":"Bondet","year":"2021","journal-title":"Cytokine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.chembiol.2020.01.010","article-title":"CRISPR-mediated protein tagging with nanoluciferase to investigate native chemokine receptor function and conformational changes","volume":"27","author":"White","year":"2020","journal-title":"Cell Chem Biol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abf1653","article-title":"Quantitative assessment of constitutive G protein-coupled receptor activity with BRET-based G protein biosensors","volume":"14","author":"Schihada","year":"2021","journal-title":"Sci Signal"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1490593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T05:10:26Z","timestamp":1734325826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1490593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2024.1490593"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1490593","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1490593"}}